252340-74-2

Upstream product

• 252340-70-8 5-Amino-2-(4-methyl-imidazol-1-yl)fluorobenzene 
• 144-55-8 sodium hydrogencarbonate 
• 501-53-1 benzyl chloroformate 
• 369-34-6 3,4-difluoronitrobenzene 
• 252337-29-4 3-fluoro-4-(4-methyl-imidazol-1-yl)nitrobenzene 

Downstream Products

• 252340-85-5 {(5R)-3-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl methanesulfonate 
• 264600-54-6 3-(4(4-methylimidazol-1-yl)-3-fluorophenyl)-5(R)-(N-(t-butoxycarbonyl)isoxazol-3-yl-aminomethyl)oxazolidin-2-one 
• 252340-78-6 (5R)-3-[3'-fluoro-4'-(4''-methyl-1''H-imidazol-1-yl)phenyl]-5-(hydroxymethyl)-oxazolidin-2-one 

Relevant academic research and scientific papers

HETEROCYCLYLAMINOMETHYLOXAZOLIDINONES AS ANTIBACTERIALS

Compounds of formula (I) or a pharmaceutically-acceptable salt, or an in-vivo hydrolysable ester thereof, wherein, for example,HET is an optionally substituted C-linked 5-membered heteroaryl ring containing 2 to 4 heteroatoms independently selected from N

Oxazolidinone derivatives with antibiotic activity

Compounds of the formula (I), or a pharmaceutically acceptable salt, or an in-vivo-hydrolysable ester thereof, wherein HET is an N-linked 5-membered heteroaryl ring, optionally substituted on a C atom by an oxo or thioxo group; and/or by 1 or 2 (1-4C)alkyl groups; and/or on an available nitrogen atom by (1-4C)alkyl; or HET is an N-linked 6-membered heteroaryl ring containing up to three nitrogen heteroatoms in total, optionally substituted on a C atom as above; Q is selected from, for example, Q1 R2 and R3 are independently hydrogen or fluoro; T is selected from a range of groups, for example, of formula (TC5) wherein Rc is, for example, R13CO—, R13SO2— or R13CS—; wherein R13 is, for example, optionally substituted (1-10C)alkyl or R14C(O)O(1-6C)alkyl wherein R14 is optionally substituted (1-10C)alkyl; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.

Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them

Compounds of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, wherein, for example, X is —O— or —S—; HET is an optionally substituted C-linked 5-membered heteroaryl ring containing 2 to 4 heteroatoms independently selected from N, O and S; Q is selected from, for example, Q1 and Q2 R2 and R3 are independently hydrogen or fluoro; T is selected from a range of groups, for example, an N-linked (fully unsaturated) 5-membered heteroaryl ring system or a group of formula (TC5): wherein Rc is, for example, R13CO—, R13SO2— or R13CS—; wherein R13 is, for example, optionally substituted (1-10C)alkyl or R14C(O)O(1-6C)alkyl wherein R14 is optionally substituted (1-10C)alkyl; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.